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Aims This randomized controlled trial (RCT) evaluated whether a process with single combined testing of copeptin and tropo-
nin at admission in patientswith low-to-intermediate risk and suspectedacutecoronarysyndrome(ACS) doesnot lead to
a higher proportion of major adverse cardiac events (MACE) than the current standard process (non-inferiority design).
Methods
and results
A total of 902 patients were randomly assigned to either standard care or the copeptin group where patients with
negative troponin and copeptin values at admission were eligible for discharge after final clinical assessment. The
proportion of MACE (death, survived sudden cardiac death, acute myocardial infarction (AMI), re-hospitalization
for ACS, acute unplanned percutaneous coronary intervention, coronary artery bypass grafting, or documented
life threatening arrhythmias) was assessed after 30 days. Intention to treat analysis showed a MACE proportion
of 5.17% [95% confidence intervals (CI) 3.30–7.65%; 23/445] in the standard group and 5.19% (95% CI 3.32–
7.69%; 23/443) in the copeptin group. In the per protocol analysis, the MACE proportion was 5.34% (95% CI
3.38–7.97%) in the standard group, and 3.01% (95% CI 1.51–5.33%) in the copeptin group. These results were
also corroborated by sensitivity analyses. In the copeptin group, discharged copeptin negative patients had an
event rate of 0.6% (2/362).
Conclusion After clinical work-up and single combined testing of troponin and copeptin to rule-out AMI, early discharge of low- to
intermediate risk patients with suspected ACS seems to be safe and has the potential to shorten length of stay in the ED.
However, our results need to be confirmed in larger clinical trials or registries, before a clinical directive can be
propagated.
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Introduction
Rule-out of acute myocardial infarction (AMI) is a major challenge
in Emergency Medicine. Around 10% of all internal medicine emer-
gency patients present to the Emergency Department (ED) with
chest pain, but only 10% of these patients have an AMI as the
underlying disease.1 Due to the potential hazards of overseeing
an evolving MI, most patients are subjected to 6–12 h observation
on chest pain units (CPU) with the effect of an excellent prognosis
at high costs.2,3
Copeptin (CT-pro-vasopressin) is a marker of acute (haemo-
dynamic) stress4 and is elevated immediately at presentation of
patients with AMI.5 A series of observational studies have shown
that due to complementary pathophysiology and kinetics, copeptin
in combination with conventional and high sensitivity (hs) cardiac
troponin (cTn) is an excellent rule-out marker for AMI5– 11 with a
high negative predictive value (NPV) of up to 99%. Some studies
were not able to reproduce this high NPV12,13 or to show an
added value when copeptin was combined with hsTn.14,15 These
results could partially be influenced by late copeptin testing,12
which impacts the ability to detect an early copeptin rise, by late
patient presentation or by the selection of patient cohorts including
high-risk patients. These factors would lead to a higher prevalence of
positive hsTn test results at presentation, thus increasing the NPV for
hsTn alone. Additionally, most studies used a copeptin assay which
did not allow choosing a cut-off below 14 pmol/L.
So far, it has not been prospectively tested whether patients with
negative copeptin and troponin test results can safely be discharged
to outpatient care. The instant rule-out of AMI has a potentially high
impact on future clinical practice, but safety of this strategy has to be
assured.
We conducted a randomized controlled trial (RCT) to assess the
safety of an early discharge after rule-out of AMI with a single com-
bined testing of troponin and copeptin at presentation to the ED/
CPU when compared with the current standard process with serial
troponin measurements in low-to-intermediate risk patients with
suspected acute coronary syndrome (ACS). The primary endpoint
was the proportion of major adverse cardiac events (MACE) at 30
days, including events during the index stay. Given that the current
process of evaluating patients with ACS is regarded as very safe, a
non-inferiority design was chosen to test the hypothesis.
Methods
Participants
This is a multi-centre, interventional clinical process RCT. The methods
are reported in full in the protocol (notfallmedizin.charite.de/forschung_
lehre/nord_campi/forschung/biomarkers_in_cardiology/). Participants
were recruited in the EDs and/or CPUs in five German, one Swiss, and
one Austrian site from April 2011 until May 2013. Patients were eligible
if they were aged ≥18 years, presented with signs and symptoms of
ACS, and had a negative troponin value at presentation. Patients were
excluded if they were diagnosed with ST-elevation myocardial infarction
(STEMI), if hospital admission was indicated due to high risk as defined in
current guidelines (continuing chest pain or recurrent episodes of chest
pain under therapy, GRACE score above 140), and if hospital admission
was necessary for any other reasons.
The study complies with the Declaration of Helsinki and received
ethics approvals from all study sites’ ethics committees. All patients pro-
vided written informed consent. The study is registered at the German
Clinical Trials Register (DRKS00000276), the International Clinical
Trials Registration platform of the WHO (UTN U1111-1118-1665),
and at ClinicalTrials.gov (NCT0149873).
Procedures
Patients were enrolled by the treating physician and randomized using 1:1
computer-generated block randomization stratified by centre (DatInfw
RandList, DatInf GmbH, Tu¨bingen). Copeptin was measured from the
same initial blood draw as the first troponin value after written informed
consent and randomization.
In the standard group, patients were managed according to the current
guidelines for the management of patients with suspected ACS. The
copeptin values were measured but not revealed to the treating staff to
assure standard care.
In the copeptin group, further patient management was dependent on
the copeptin result. In case of a negative result, patients were considered
low risk and could be discharged into ambulant care. Before discharge,
patients had a final visit to secure their well-being. The final discharge
decision was at the discretion of the attending physician who was
allowed to overrule the biomarker result. All discharged patients had
an outpatient cardiology appointment within a maximum of 3 days
after discharge. In case of a positive copeptin result, patients were
managed like the standard group.
All patients were contacted at 30 days to assess their outcome
(Supplementary material online, Figure S1).
Outcome
Primary endpoint was the proportion of combined MACE, defined as
all-cause death or survived sudden cardiac death, AMI, re-hospitalization
for ACS, acute unplanned percutaneous coronary intervention (PCI),
coronary artery bypass grafting (CABG), and documented life-
threatening arrhythmias (ventricular tachycardia, ventricular fibrillation,
atrio-ventricular-block III) within 30 days, including events during the
index hospital stay.
Acute myocardial infarction was defined as per Universal Definition.16
Every patient was assigned only one MACE with priority of the event that
occurred first.
Secondary endpoints were proportion of coronary angiography (CA),
split MACE at 30 and all MACE at 90 days, major bleeding events (as per
TIMI definition), and length of stay (LOS).
All MACE and bleeding events were adjudicated by two independent
Cardiologists blinded to copeptin result and group assignment.
Biomarker testing
Copeptin was measured from the routine blood sample at admission,
using the Thermo Scientific B.R.A.H.M.S Copeptin ultrasensitive
Kryptor assay. The assay has a detection limit of 0.9 pmol/L and a func-
tional assay sensitivity of ,2 pmol/L. A value of 10 pmol/L and above
was considered positive. The cut-off was chosen with reference to
Keller et al.5 who determined different cut-offs in a reference population
and tested the diagnostic performance of these cut-offs in an ACS
population.
Troponin was tested as by routine practice at the individual sites. A
conventional troponin T (TnT) POCT assay (AQT 90 -Radiometer)
was used at two sites (cut-off .30 ng/L).
High-sensitive TnT (Roche) was used at four sites for all and at two sites
for further serial troponin measurements (cut-off .14 ng/L). One site
used troponin I (Siemens Dimensionw-System) (cut-off level 56 ng/L)
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until November 2012 and troponin I (Siemens Dimension Vistaw-System)
thereafter (cut-off level 45 ng/L).
Additional blood samples were drawn as per standard practice after
3–6 h.
Statistical analysis
All data were entered into an online electronic case report form. Statis-
tical analyses were performed using the software packages SPSS (IBMw
SPSS Statistics, Version 21) and SAS Version 9.3 (SASw Institute Inc.).
Statistical testing of categorical variables was performed using exact
binomial tests; for numerical variables, t-tests (in case of normal distri-
bution) or Wilcoxon tests (no normal distribution) were used. For the
comparison between more than two groups, Kruskall–Wallis test was
used. A P-value below 0.05 was considered significant.
The study hypothesis was non-inferiority of the copeptin process
against the standard process regarding the primary endpoint. The
power calculation was based on an anticipated proportion of MACE
within 30 days of 10%.17– 19 Confidence intervals (CI) for differences
were calculated as one-sided 97.5% CI using the Wilson procedure
with a correction for continuity.20 The non-inferiority margin was set
at 5%. Note: This means, that non-inferiority of the new process can be
accepted if the lower bound of the one-sided 97.5% CI of MACE differ-
ence between both study groups does not exceed the 5% margin. The
rationale for this margin was based on own data, previous studies, and
expert consensus. The sample size calculation resulted in a required
number of 446 participants per group (892 overall) with a power of
80% and a level of significance of 5%.
In the intention to treat (ITT) analysis for the primary endpoint, all
patients were analysed as randomized irrespective of protocol devia-
tions, excluding all patients with an unknown outcome.
In the per protocol (PP) analysis, all patients with protocol deviations
(n ¼ 40), over-rulers (n ¼ 71), as well as patients with unknown
outcome (n ¼ 14) were excluded. Additionally, sensitivity analyses, as-
suming that all patients who were lost to follow-up (FU) (n ¼ 14) devel-
oped either a good (no MACE) or a poor (MACE) outcome, were
conducted. Patients with protocol deviations were not excluded from
this sensitivity analysis and were analysed as randomized. Confidence
intervals for the primary endpoint were calculated as exact binomial
95% CIs.
Results
Patient characteristics
A total of 902 patients were randomized to either the standard
(n ¼ 451) or the copeptin (n ¼ 451) group (Figure 1). Randomisation
proved successful with very similar patient characteristics, risk
profile, and medical history profile in the two groups (Table 1).
Outcome
A total of 46 of all patients developed a MACE during the 30-day FU
period. The absolute number of patients with MACE was equal
between the two groups (n ¼ 23 for both;Table 2, Figure 2). Intention
to treat analysis showed a MACE proportion of 5.17% (95% CI 3.30–
7.65%) in the standard group and 5.19% (95% CI 3.32–7.69%) in the
copeptin group (Table 2). In the PP analysis, the MACE proportion
was 5.34% (95% CI 3.38–7.97%) in the standard group, and 3.01%
(95% CI 1.51–5.33%) in the copeptin group. In all four sensitivity
analyses, including extreme case analyses, the non-inferiority
margin was not exceeded by the one-sided 97.5% CI (Figure 3).
More informationon theoutcomedataof thecompoundendpoint
is shown in Supplementary material online, Table S1 and Supplemen-
tary material online, Figure S2. No MIs or deaths occurred in the dis-
charged copeptin-negative patients of the copeptin group. Detailed
information on copeptin-negative patients with MACE is shown in
the Supplementary material online, Table S3. Diagnoses, in-hospital
course, in-hospital procedures, and length of hospital stay are
shown in Supplementary material online, Table S2. Of all patients,
39.8% (359/902) were discharged from the ED. In the copeptin
group, 67.6% (305/451) were discharged from the ED as opposed
to 12.0% (54/451) in the standard group (P, 0.001; Table 3).
Of the copeptin-negative patients in the copeptin group, 80.7%
(296/367) were discharged from the ED, as opposed to 11.6% (41/
353) of copeptin negative patients in the standard group
(P, 0.001; Supplementary material online, Table S2). The LOS for
patients discharged after MI exclusion was analysed in all patients
who were discharged the same day, or the day after presentation
to the ED in order to also include patients who were admitted to
the CPU for ACS evaluation. Median LOS was significantly shorter
in the copeptin group (4 (IQR 2–6) h) than in the standard group
(7 (IQR 4–9) h, P, 0.001).
The PCI/CA ratio was higher in the copeptin group (47.3%) when
compared with the standard group (36.6%), without reaching
statistical significance (P ¼ 0.307; Table 3).
Discussion
The current study provides evidence that with appropriate clinical
selection of low-to-intermediate risk patients with suspected ACS,
the combination of negative troponin and negative copeptin at pres-
entation on the basis of a thorough clinical evaluation helps identify
patients who can safely be discharged into outpatient care. The
MACE proportion at 30 days did not differ between the two
groups confirming non-inferiority of the new process. Secondary
endpoint analysis shows that the new process is effective with a
reduced length of hospital stay and a higher proportion of discharges
directly from the ED.
Standard process and promises of high
sensitivity cardiac troponin
The standard clinical process for the acute diagnostic assessment of
suspected ACS is described in current guidelines.21 These guidelines
focus on troponin measured with hs assays and on delta changes, as a
number of observational studies have shown that the new assay gen-
eration might enable rule-in and rule-out of AMI earlier than conven-
tional assays.22– 24 The exact definition of relevant troponin changes
is an important andyetunsolved issue.Recentpublications showcon-
flicting delta values25,26 and, additionally, minor delta changes may
also occur in patients with AMI.27 Additionally, hs assays identify a
high number of patients with elevated troponin results without
AMI, making interpretation of test results challenging. There are no
interventional studies, which prospectively tested whether fast
rule-out strategies with serial hsTn alone are effective and safe.
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The new process
The current process of evaluating patients with suspected ACS is
regarded as safe.21 Any new process has got to prove that patient
safety is not decreased by applying the new process and that it
holds advantages beyond safety.
The biomarker strategy of a combined copeptin-troponin rule-out
of AMI has been analysed in a number of retrospective observational
biomarker studies,5,7,8 but this is the first interventional RCT evaluat-
ing the safety of early discharge. Clinicians may use the new strategy
for a fast track which reserves space and resources for more severely
ill patients. In addition, unnecessary treatment with anti-platelet and
anti-thrombotic medications can be avoided, reducing the risk of
bleeding complications. The shorter LOS potentially reduces risks
of hospitalization, stress, and anxiety.
Figure 1 Consort flow diagram. A total of 13 patients were excluded from the study (6 patients withdrew, of 3 patients in the copeptin group,
copeptin values were not available, 2 patients were troponin positive at admission, 1 patient had a ST-elevation myocardial infarction at admission, 1
patient had been randomized previously). In 72 copeptin-negative patients in the copeptin group, the treating physician decided that discharge was
not possible, 71 of them were admitted to the chest pain units, 1 refused to be admitted. A total of 14 patients (1.6%) were lost to follow-up (FU) at 30
days and not considered in the complete case analysis, 8 in the copeptin and 6 in the standard group, the in-hospital FU was available for all patients.
*n ¼ 1 randomized 12 h after admission; n ¼ 1 suspected aortic dissection at admission; **n ¼ 5 patients were lost to 30d-FU but included in the
complete case analysis (ITT). Of those n ¼ 4 had an in-hospital major cardiac events (MACE), one patient did not have an initial event but his death
date was identified in the German central registry.
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Safety issues of the new process
Previous copeptin studies have faced criticism because the NPV is not
100% and some people may argue that it is not safe to implement a
strategy which seems to ‘fail’ in some patients. The combined end-
point in our study was mainly driven by PCIs performed during the
index hospital stay, whereas severe events like AMI and death were
rare and occurred in-hospital only. Most probably, those PCIs were
not triggered only by ‘urgency’ but also by ‘occasion’.
The component ‘urgent PCI’ was added to the combined endpoint
as we did not want to oversee PCIs after discharge which may have
prevented MIs or deaths and therefore could have masked risks in
the discharged group. The event rate in copeptin-negative patients
discharged was in fact very low (0.6%). Life-threatening events
were not detected in copeptin-negative patients.
Inour study,81.4%ofpatients in thecopeptin groupwerecopeptin
and troponin negative. In 71 cases, the treating physician decided
to overrule the negative marker result and to admit the patient to
the CPU. This is an acceptable rate of overruling as the clinical
responsibility needs to be in the hands of the attending physician
and a ‘traditional’ and known process is usually favoured. Of the 14
copeptin-negative patients with MACE, 12 were not discharged
despite their negative biomarker result. Of these, two patients
were diagnosed with an NSTEMI during the initial hospital stay, but
did not profit from a coronary intervention. The two copeptin-
negative patients with MACE who were discharged had (i) an un-
planned PCI and (ii) CABG surgery in the 30-day FU period. This is
not surprising as copeptin is not a marker of coronary artery
disease and the initial discharge was safe for both patients. Neverthe-
less, it should be highlighted that the patients in this study were sched-
uled for a cardiology outpatient visit within three working days and
therefore a diagnostic workup was facilitated.
Limitations
A rapid rule-out of AMI with the combined biomarker testing from a
single blood draw at admission is bound to cause concerns in some phy-
sicians who are used to 20 years of serial biomarker (troponin)
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Table 1 Characteristics of all patients and in the study groups
All patients (n 5 902) Standard group (n 5 451) Copeptin group (n5 451)
Patient characteristics
Age (years) (mean+ SD) 54.1+15.6 54.1+15.1 54.1+16.2
Male sex 63.2 (570) 65.4 (295) 61.0 (275)
Risk factors
BMI 27.3+4.86 27.3+4.64 27.3+5.1
Diabetes 13.6 (123) 14.0 (63) 13.3 (60)
Hypertension 57.5 (519) 57.0 (257) 58.1 (262)
Hyperlipidaemia 43.5 (392) 45.2 (204) 41.7 (188)
Family history of MI 25.5 (230) 22.2 (100) 28.8 (130)
Smoker 32.4 (292) 33.7 (152) 31.0 (140)
Ex-smoker 30.8 (278) 30.2 (136) 31.5 (142)
GRACE-score (mean+ SD) 80.32+27.6 79.8+27.6 80.9+27.5
TIMI risk score (Median/IQR) 1 (0–3) 1 (0–2) 1 (0–3)
Medical history
Known CAD 25.7 (232) 24.6 (111) 26.8 (121)
Prior MI 14.6 (132) 15.3 (69) 14.0 (63)
Prior PCI 22.2 (200) 22.1 (100) 22.2 100)
Prior CABG 5.0 (45) 3.5 (16) 6.4 (29)
Chronic heart failure 5.8 (52) 4.2 (19) 7.3 (33)
Primary valve disease 6.9 (62) 7.1 (32) 6.7 (30)
Prior valve surgery 1.2 (11) 0.9 (4) 1.6 (7)
Cardiomyopathy 2.1 (19) 1.1 (5) 3.1 (14)
Renal disease 6.2 (56) 4.9 (22) 7.5 (34)
Time since symptom onset
0–3 h 43.2 (345) 43.8 (178) 42.6 (167)
,6 h 54.8 (437) 54.4 (221) 55.1 (216)
,12 h 64.0 (511) 62.3 (253) 65.8 (258)
Missing data n ¼ 104 n ¼ 45 n ¼ 59
Patient characteristics at admission of all patients and in the studygroupsas randomized. Data are shownas percent (numbers)or as stated. Abbreviations: SD, standarddeviation; IQR,
inter quartile ranges; BMI, body mass index.
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measurements.Ourstudywasperformed in theEDsunderroutinecon-
ditionsandbytheroutineEDphysicians.Considering this, thenumberof
cross-overs in our study (n¼ 71) should be judged as low; the majority
of copeptin-negative patients were discharged early. It needs to be
emphasized that any biomarker strategy must be embedded in a
process of thorough physician work-up and clinical judgement.
A total number of 19 patients (2.1%, Figure 1) were lost to
FU, which is an acceptable rate but may still have influenced
the results of the trial. Notably, even the worst-case scenario
sensitivity analysis, assuming a negative outcome for all patients
lost to FU in the copeptin group, did not change the primary
result of our study.
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Table 2 Primary endpoint analyses
Standard group
(n 5 451)
Copeptin group
(n5 451)
Absolute difference in MACE
proportion (97.5% one-sided CI)
MACE at 30 days
Yes 23 23 –
No 422 422 –
Unknown 6 8 –
MACE % (95% CI): (absolute numbers)
Intention to treat analysis 5.17 (3.30–7.65) (23/445) 5.19 (3.32–7.69) (23/443) 20.02 (22.94)
Per protocol analysis 5.34 (3.38–7.97) (22/412) 3.01 (1.51–5.33) (11/365) 2.33 (20.46)
Sensitivity analyses
Assuming poor outcome 6.43 (4.35–9.10) (29/451) 6.87 (4.72–9.61) (31/451) 20.44 (23.70)
Assuming good outcome 5.10 (3.26–7.55) (23/451) 5.10 (3.26–7.55) (23/451) 0.00 (22.87)
Extreme case: favouring standard group 5.10 (3.26–7.55) (23/451) 6.87 (4.72–9.61) (31/451) 21.77 (24.87)
Extreme case: favouring copeptin group 6.43 (4.35–9.10) (29/451) 5.10 (3.26–7.55) (23/451) 1.33 (21.71)
Analysis of the primary endpoint: All MACE within 30 days.
The CIs for the absolute difference between the proportions in the respective study groups did not exceed the 5% non-inferiority margin in any analysis, confirming non-inferiority of
the copeptin based process as hypothesized, even if the worst case was assumed.
Figure 2 Major adverse cardiac events (MACE) proportions in study groups and in copeptin subgroups. Patients were randomized into copeptin
and standard group, where MACE proportions were very similar. Copeptin results were only revealed to the treating staff in the copeptin group. In
subgroups of copeptin-positive and copeptin-negative patients, major adverse cardiac event (MACE) rates are higher in copeptin positives. MACE
proportions are lowest in discharged copeptin-negative patients.
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Due to the high number of cross-overs in the copeptin-negative
study group (n ¼ 71), the results of the PP analysis, which suggests
superiority of the copeptin-guided process, should be interpreted
with caution.
The non-inferiority margin in this study (5%) was based on an
anticipated event rate of 10%. This estimate was the result of a
review of own data and historical studies.17 –19 The actually observed
event rate in our study, however, was 5.2% and was thus lower than
expected. This lower event rate could be explained by the fact that
the availability of cardiac catheterization laboratories has increased
significantly during recent years and most hospitals use invasive
diagnostic strategies in chest pain patients very liberally. Thus, it
would be possible that a number of patients with intermediate risk
(who would have been eligible to participate) were not included
because discharge was not considered.28 The low observed event
rate renders the non-inferiority margin relatively wide (relative to
the event rate) and thus impacts the relevance of the statistical
results which therefore need further confirmation by other clinical
trials or registries before they can be regarded as clinically directive.
Conclusion
As for all new interventional strategies or therapies, it will be of major
interest to evaluate the safety and effectiveness of this strategy under
routine conditions and in a larger number of patients. The introduc-
tion of registries at sites who implement the new strategy will show
whether the new concept is really safe or—as some fear—will be
abused by busy ED physicians. The current study provides evidence
that on the basis of a thorough clinical work-up and single combined
testing of troponin and copeptin at presentation to rule-out AMI,
early discharge of low-to-intermediate risk patients with suspected
ACS seems to be safe, has the potential to shorten LOS in the ED,
and may therefore benefit the patient. However, as a consequence
of the relatively wide non-inferiority margin, our results need to be
Figure 3 Forest plot for differences in major adverse cardiac
event (MACE) proportions. Absolute differences in MACE propor-
tions within 30 days between the study groups with one-sided
97.5% CIs. The non-inferiority margin was prospectively defined
at 5%. In none of the performed analyses, the non-inferiority
margin was exceeded.
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Table 3 Secondary endpoints
All patients n 5 (902) Standard group (n5 451) Copeptin group (n 5 451) P-value
In-hospital course
Discharge from ED 39.8 (359) 12.0 (54) 67.6 (305) ,0.001
Index in-hospital procedures
CA 10.6 (96) 9.1 (41) 12.2 (55) 0.132
PCI 4.6 (41) 3.3 (15) 5.8 (26) 0.080
PCI/CA ratio (%) 42.7 36.6 47.3 0.307
CABG 0.2 (2) – 0.4 (2) –
LOS in % (n)
0–1 day 85.1 (767) 84.9 (383) 85.1 (384) 1.000
2–5 days 11.3 (102) 12.4 (56) 10.2 (46) 0.344
.6 days 3.7 (33) 2.7 (12) 4.7 (21) 0.155
LOS in hours (median/IQR)
LOS for all patients 6 (4–11) 7 (5–13) 4 (3–8) ,0.001
LOS in 0–1-day groupa 5 (4–8) 7 (4–9) 4 (2–6) ,0.001
Major bleedings in % (n) 0.4 (4) 0.2 (1) 0.7 (3) 0.573
Secondary endpoints in all patients and in the respective study groups.
aThe LOS for patients discharged after MI exclusion was analysed in all patients who were discharged the same day, or the day after presentation to the ED in order to include patients
who were admitted to the CPU for ACS evaluation.
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confirmed in larger clinical trials or registries, before a clinical
directive can be propagated.
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Supplementary material is available at European Heart Journal online.
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